News
- May 20, 2026
VentiraDx Returns from AUA 2026 with Strengthened Confidence in TAGMeTM Commercialization; Product Launch Preparations Underway
BURLINGTON, Mass., May 20, 2026 — VentiraDx today announced that the company successfully participated in the 2026 American Urological Association (AUA) Annual Meeting, held May 15–18, 2026, in Washington, D.C. During the meeting, the VentiraDx team engaged in in-depth discussions with numerous urologists and uro-oncology specialists, gaining direct clinical insight that has further validated the commercial potential of TAGMeTM for urothelial carcinoma recurrence monitoring.